GlassScriptPhysician profile
Roberto Enrique Pancorbo
NPI 1730293911
$2,051.57
in general payments reported to CMS, 2019-2025
18 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.48 · 2020: $51.46 · 2021: $84.54 · 2023: $826 · 2024: $767 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.09 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $436.09 | 2020-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $277.43 | 2020-2024 | Tremfya |
| Ucb, INC. | $276.24 | 2019-2024 | Cimzia |
| Abbvie INC. | $258.75 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $210.06 | 2024-2025 | Acthar |
| Glaxosmithkline, LLC. | $103.01 | 2023-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $96.59 | 2024-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $92.47 | 2019-2024 | |
| Genentech USA, INC. | $50.56 | 2020-2023 | Actemra |
| Astrazeneca Pharmaceuticals LP | $47.83 | 2024-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $39.40 | 2023 | Lupkynis |
| Lilly USA, LLC | $32.63 | 2023 | Taltz |
| Sandoz INC. | $32.39 | 2024 | Hyrimoz |
| Kyowa Kirin, INC. | $22.82 | 2023 | Crysvita |
| Genzyme Corporation | $22.13 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2023 | |
| Horizon Therapeutics Plc | $18.47 | 2023 | Krystexxa |
| Pfizer INC. | $16.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Pancorbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.